SOLU-KNEX®
Solubility-Enhancing ADC Linkers
About SOLU-KNEX®
Built on well-established ADC linker architectures, SOLU-KNEX® ADC linkers feature integrated solubilizing moieties, such as polyethylene glycol (PEG), amine-containing groups, or polysarcosine (PSAR), to dramatically enhance aqueous solubility. By carefully selecting and combining these groups, the linkers offer tunable physicochemical properties, reducing aggregation, improving stability, and enabling higher drug loading. This flexibility makes SOLU-KNEX® ADC linkers highly adaptable, supporting streamlined formulation, consistent manufacturing, and the development of next-generation ADCs with optimized efficacy and therapeutic performance.
Why Solubility Matters
Solubility is a critical determinant of ADC success because it directly impacts stability, safety, efficacy, and manufacturability throughout development and clinical use. Poorly soluble ADCs are prone to aggregation, which can reduce target binding, alter pharmacokinetics, increase immunogenicity, and raise the risk of off-target toxicity. Adequate solubility enables higher drug loading, more flexible formulation options, and consistent large-scale manufacturing, while supporting predictable biodistribution and controlled payload delivery in vivo. Optimizing solubility is essential to maximizing the therapeutic index and ensuring the developability of effective, reliable antibody–drug conjugates.
SOLU-KNEX® Advantages
Validated Core
SOLU-KNEX® ADC linkers are built upon clinically validated ADC linker chemistries, such as MC-VC-PAB (maleimidocaproyl–valine–citrulline–p-aminobenzyl), leveraging their proven in vivo stability and highly efficient intracellular payload release.
Tunable Solubility
SOLU-KNEX® ADC Linkers feature a tunable chemical design that allows precise adjustment of their hydrophobicity, polarity, and overall chemical composition, enabling significantly improved solubility for a wide range of payloads and conjugation chemistries.
Broad Applications
SOLU-KNEX® ADC linkers are well positioned to support emerging ADC research, including dual-drug ADCs, AOCs (antibody–oligonucleotide conjugates), iADCs (immune-stimulating antibody–drug conjugates), DACs (degrader–antibody conjugates), and ARCs (antibody–radionuclide conjugates), and more.
SOLU-KNEX® is a registered trademark of Tenova Pharmaceuticals, Inc.